FORUM Study Reveals Grafalon's Benefits for High-Risk Pediatric HSCT Patients

Neovii Pharmaceuticals AG disclosed findings from the FORUM study, evaluating Grafalon's impact on pediatric HSCT patients. The large phase 3 study assessed serotherapy outcomes in those undergoing matched unrelated donor HSCT.

The study covered children and young adults with acute lymphoblastic leukemia. It compared Grafalon with another anti-thymocyte globulin in patients based on conditioning regimens. Over 1,100 participants contributed to the results.

Grafalon showed reduced chronic GvHD and fewer viral infections in patients aged four years or older. For younger children receiving chemotherapy, Grafalon led to higher event-free survival rates. However, no significant differences were found for children over four years using chemotherapy-based conditioning.

These results underscore Grafalon's potential in improving high-risk pediatric HSCT outcomes and Neovii intends to seek further regulatory approvals.